Symptom management care pathway adaptation process and specific adaptation decisions

  • Emily Vettese (Creator)
  • Farha Sherani (Creator)
  • Allison A. King (Creator)
  • Lolie C. Yu (Creator)
  • Catherine Aftandilian (Creator)
  • Christina Baggott (Creator)
  • Vibhuti Agarwal (Creator)
  • Ramamoorthy Nagasubramanian (Creator)
  • Kara M. Kelly (Creator)
  • David R. Freyer (Creator)
  • Etan Orgel (Creator)
  • Scott M. Bradfield (Creator)
  • Wade Kyono (Creator)
  • Michael E. Roth (Creator)
  • Lisa M. Klesges (Creator)
  • Melissa Beauchemin (Creator)
  • Allison C Grimes (Creator)
  • George Tomlinson (Creator)
  • Lee Dupuis (Creator)
  • Lillian Sung (Creator)
  • Allison A. King (Creator)
  • Lolie Yu (Creator)
  • L. Lee Dupuis (Creator)
  • Lillian Sung (Creator)

Dataset

Description

Abstract Background There is substantial heterogeneity in symptom management provided to pediatric patients with cancer. The primary objective was to describe the adaptation process and specific adaptation decisions related to symptom management care pathways based on clinical practice guidelines. The secondary objective evaluated if institutional factors were associated with adaptation decisions. Methods Fourteen previously developed symptom management care pathway templates were reviewed by an institutional adaptation team composed of two clinicians at each of 10 institutions. They worked through each statement for all care pathway templates sequentially. The institutional adaptation team made the decision to adopt, adapt or reject each statement, resulting in institution-specific symptom management care pathway drafts. Institutional adaption teams distributed the 14 care pathway drafts to their respective teams; their feedback led to care pathway modifications. Results Initial care pathway adaptation decision making was completed over a median of 4.2 (interquartile range 2.0-5.3) weeks per institution. Across all institutions and among 1350 statements, 551 (40.8%) were adopted, 657 (48.7%) were adapted, 86 (6.4%) were rejected and 56 (4.1%) were no longer applicable because of a previous decision. Most commonly, the reason for rejection was not agreeing with the statement (70/86, 81.4%). Institutional-level factors were not significantly associated with statement rejection. Conclusions Acceptability of the 14 care pathways was evident by most statements being adopted or adapted. The adaptation process was accomplished over a relatively short timeframe. Future work should focus on evaluation of care pathway compliance and determination of the impact of care pathway-consistent care on patient outcomes. Trial registration clinicaltrials.gov, NCT04614662. Registered 04/11/2020, https://clinicaltrials.gov/ct2/show/NCT04614662?term=NCT04614662&draw=2&rank=1 .
Date made available2023
PublisherFigshare

Cite this